Fundraising Fox
/Companies
Sign in

ProTgen

Toronto · Founded 2023 · 2 known investors

Find your way into ProTgen

Sign up to find every way you can get introduced to ProTgen

  • Your email: who you already know at ProTgen, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the ProTgen team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

ProTgen is a clinical-stage biotechnology company developing targeted Notch activators that generate progenitor T cells to restore thymic function and adaptive immune competence. Its work spans ex vivo cell therapy (ProT-096) and in vivo biologic programs (RGT-096).

BiotechHealthtech

Founders & leadership

ProTgen was founded in 2023 by Juan Carlos Zuniga-Pflucker.

JC
Juan Carlos Zuniga-PfluckerFounder

Board

FS
Fei ShenBoard director
FM
Ferdinand MassariBoard director

Investors · 2

FACIT (Fight Against Cancer Innovation Trust)listed by FACIT (Fight Against Cancer Innovation Trust)Toronto · $1.1M

How we know: FACIT (Fight Against Cancer Innovation Trust)'s portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$8.2M disclosed across 1 round · 2024

▶$8.2MraisedDec 2024 · 4 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Fei ShenDirector
  • Juan Carlos Zuniga-PfluckerExecutive Officer, Director
  • Ferdinand MassariDirector
Offering amount
$20M
Amount sold
$8.2M
First sale
Nov 2024
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

PepGenPepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.

Companies working in the same space as ProTgen.

Frequently asked questions

What does ProTgen do?
ProTgen is a clinical-stage biotechnology company developing targeted Notch activators that generate progenitor T cells to restore thymic function and adaptive immune competence. Its work spans ex vivo cell therapy (ProT-096) and in vivo biologic programs (RGT-096).
Who founded ProTgen?
ProTgen was founded by Juan Carlos Zuniga-Pflucker in 2023.
Who are ProTgen's investors?
ProTgen's investors include Eisai Innovation, Inc., FACIT (Fight Against Cancer Innovation Trust).
How much funding has ProTgen raised?
ProTgen has disclosed $8.2M raised across 1 round.
Where is ProTgen headquartered?
ProTgen is headquartered in Toronto.